Calidi Biotherapeutics ( (CLDI) ) has shared an announcement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Calidi Biotherapeutics, a biotechnology company specializing in targeted antitumor therapies, has been notified by the NYSE that its warrants, trading under CLDI WS, will be delisted due to low trading prices. However, trading of Calidi’s common stock, CLDI, remains unaffected. The company is exploring options to appeal the decision. Calidi continues its focus on developing innovative cancer treatments through its stem cell-based platforms.
Find detailed analytics on CLDI stock on TipRanks’ Stock Analysis page.